Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF) Sees Significant Increase in Short Interest
Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF) Sees Significant Increase in Short Interest
Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF – Get Rating) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,500 shares, an increase of 1,400.0% from the July 31st total of 100 shares. Based on an average daily volume of 2,300 shares, the short-interest ratio is presently 0.7 days.
Ortho Regenerative Technologies Inc.(OTCMKTS：ORIF-GET Rating)是8月份空頭股數大幅上漲的接受者。截至8月15日，空頭股數共有1,500股，比7月31日的100股增加了1,400.0%。以日均成交量2,300股計算，目前短息比率為0.7天。
Ortho Regenerative Technologies Price Performance
正射再生技術性價比
OTCMKTS:ORTIF remained flat at $0.20 on Friday. The company has a market cap of $6.86 million, a P/E ratio of -1.78 and a beta of -1.22. Ortho Regenerative Technologies has a 1 year low of $0.13 and a 1 year high of $0.45. The firm's fifty day moving average is $0.20 and its 200-day moving average is $0.19.
OTCMKTS：ORTIF週五持平於0.20美元。該公司的市值為686萬美元，市盈率為-1.78，貝塔係數為-1.22。Ortho Regenerative Technologies的一年低點為0.13美元，一年高位為0.45美元。該公司的50日移動均線切入位為0.20美元，200日移動均線切入位為0.19美元。
Ortho Regenerative Technologies (OTCMKTS:ORTIF – Get Rating) last announced its quarterly earnings results on Thursday, June 23rd. The company reported ($0.02) EPS for the quarter. Analysts predict that Ortho Regenerative Technologies will post -0.08 earnings per share for the current fiscal year.
Ortho Regenerative Technologies(OTCMKTS：ORTIF-GET Rating)最近一次公佈季度收益是在6月23日星期四。該公司公佈了該季度每股收益(0.02美元)。分析師預測，Ortho Regenerative Technologies本財年的每股收益將為0.08美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Ortho Regenerative Technologies Company Profile
Ortho再生技術公司簡介
(Get Rating)
(獲取評級)
Ortho Regenerative Technologies Inc, an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration.
Ortho Regenerative Technologies Inc是一家整形外科和運動醫學生物製劑公司，致力於研究和開發新型治療性軟組織修復技術，以提高加拿大運動醫學手術的成功率。它開發了用於肩袖修復的Ortho-R配方、用於半月板修復的生物聚合物Ortho-M、用於關節軟骨修復的生物聚合物Ortho-C、用於骨關節炎癒合的生物聚合物Ortho-V以及用於肌腱癒合和再生的生物聚合物配方Ortho-T。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Ortho Regenerative Technologies (ORTIF)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- 免費獲取StockNews.com關於正畸再生技術的研究報告(ORTIF)
- 為什麼進軍高級汽車零部件可能是一個機會
- MarketBeat：回顧中的一週8/22-8/26
- 機構買入讓Marvell科技陷入低谷
- 戴爾股票因銷售疲軟而回落，跌入可怕的價值
- Dollar General的拉力賽有三個理由
Receive News & Ratings for Ortho Regenerative Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ortho Regenerative Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《正畸再生技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ortho再生技術公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。